Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H. Lundbeck ASSTU:LDBA +1.41%70 EV-to-OCF is 9.24 as of Aug. 18, 2026, which is 12% above its 10-year median of 8.24. GuruFocus rates STU:LDBA with a GF Score™ of 70/100 and a GF Value™ of €6.37 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, H. Lundbeck AS ranks better than 54.63% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, H. Lundbeck AS's Enterprise Value is €6,746 Mil.
H. Lundbeck AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €730 Mil. Therefore, H. Lundbeck AS's EV-to-OCF for today is 9.24.
The historical rank and industry rank for H. Lundbeck AS's EV-to-OCF or its related term are showing as below:
STU:LDBA'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.29 Med: 8.24 Max: 19.57
Current: 9.15
During the past 13 years, the highest EV-to-OCF of H. Lundbeck AS was 19.57. The lowest was 5.29. And the median was 8.24.
STU:LDBA's EV-to-OCF is ranked better than 54.63% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 11
vs STU:LDBA: 9.15
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
H. Lundbeck AS's PE Ratio (TTM) for today is calculated as:
H. Lundbeck AS's share price for today is €5.745.
H. Lundbeck AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.499.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
H. Lundbeck AS EV-to-OCF Related Terms
H. Lundbeck AS EV-to-OCF Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's EV-to-OCF falls into.
H. Lundbeck AS's current Enterprise Value is €6,746 Mil.
H. Lundbeck AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €730 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H. Lundbeck AS (STU:LDBA) has a EV-to-OCF of 9.24 as of Aug. 18, 2026. This is 12% above median its historical median of 8.24. Over the past decade, H. Lundbeck AS's EV-to-OCF has ranged from 5.29 to 19.57. According to the industry distribution chart, H. Lundbeck AS ranks #456 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is H. Lundbeck AS's EV-to-OCF too high?
H. Lundbeck AS's current EV-to-OCF of 9.24 is 12% above median its 10-year median of 8.24. Over the past 10 years, this metric has ranged from a low of 5.29 to a high of 19.57. The Drug Manufacturers industry median EV-to-OCF is 11.00. H. Lundbeck AS's value of 9.24 is 16% below this industry median. Based on the distribution chart, H. Lundbeck AS ranks #456 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #456 out of 1005 companies for EV-to-OCF. This puts H. Lundbeck AS in the upper half of its industry. The industry median EV-to-OCF is 11.00. H. Lundbeck AS's value of 9.24 is 16% below this benchmark. Historically, H. Lundbeck AS's own EV-to-OCF has ranged from 5.29 to 19.57 over the past decade. While the company's 10-year median is 8.24 vs. the industry median of 11.00, H. Lundbeck AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.00, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current EV-to-OCF of 9.24 is 16% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current EV-to-OCF is 9.24, which is 12% above median its own 10-year median of 8.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (STU:LDBA) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.37, compared to a current price of €5.75 — trading 9.8% below its estimated fair value. The current EV-to-OCF is 9.24, which is 12% above median its 10-year median of 8.24 and 16% below the Drug Manufacturers industry median of 11.00. H. Lundbeck AS's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For H. Lundbeck AS (STU:LDBA), the current EV-to-OCF is 9.24 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (STU:LDBA) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of €5.75 is trading 9.8% below its estimated GF Value™ of €6.37.
GuruFocus considers H. Lundbeck AS to be Modestly Undervalued.
Key valuation signals for STU:LDBA:
EV-to-OCF: 9.24 (12% above median its 10-year median of 8.24)
GF Value™: €6.37 vs. price of €5.75 (9.8% below fair value)
Industry Position: 16% below the Drug Manufacturers median (#456 of 1005)
No single metric tells the full story. See the STU:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
70GF Score
Get the complete analysis for STU:LDBA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LDBA has been successfully added to your 
